×
Log in
Upload File
Most Popular
Study
Business
Design
Technology
Travel
Explore all categories
Download -
Opdivo INN: 'nivolumab' · Start of procedure: 17 September 2016 CHMP Co-Rapporteur Assessment Report 16 November 2016 CHMP Rapporteur Assessment Report 21 November 2016 PRAC Rapporteur
Download
Top Related
CHMP extension of indication variation assessment …...London, 24 July 2014 EMA/562197/2014 Committee for Medicinal Products for Human Use (CHMP) CHMP extension of indication variation
Assessment report - European Medicines Agency · March 2016. • The Rapporteur circulated the Assessment Report on the applicant’s responses to the List of Questions to all CHMP
OPDIVO, INN-nivolumab
European Medicines Agency | - authorised...submitted on 16 August 2007 their dossier in response to the quality issues raised by the CHMP and EMEA. On 7 September 2007, the Rapporteur
AUSTRALIAN PRODUCT INFORMATION OPDIVO (NIVOLUMAB)OPDIVO, as monotherapy, is indicated for the treatment of locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC)
CHMP assessment report - Europa
CHMP assessment report - European Medicines Agency€¦ · CHMP assessment report EMA/CHMP/272283/2016 Page 3/86 intolerant to or have medical contraindications for such therapies
CHMP assessment report€¦ · CHMP assessment report EMA/CHMP/208477/2013 Page 9/136 September 2012. The Co-Rapporteur's first Assessment Report was circulated to all CHMP members